Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports the resolutions passed at the 144th Ordinary General Meeting of Shareholders held on June 24, 2020. The filing covers matters related to the 143rd fiscal year, which ran from April 1, 2019, to March 31, 2020.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. It references the Consolidated Financial Statements for the 143rd fiscal year as having been reported to shareholders but does not include the numerical data within this document.
Key financial resolutions include:
- Dividend: A year-end dividend of 90 JPY per share was approved.
- Director Bonuses: A total bonus pool of up to 1,100 million JPY was approved for three eligible directors (excluding overseas and external directors).
Material Changes
The filing does not contain comparative financial data or details on material changes in operations versus the prior period. It focuses on corporate governance actions taken at the shareholder meeting.
Guidance, Outlook, and Governance
Management Commentary and Risks: The document contains no forward-looking guidance, outlook, or discussion of risks and contingencies.
Governance Resolutions:
- Directors Re-elected: Twelve directors who are not Audit and Supervisory Committee members were re-elected, including President Christophe Weber. Eight of these are classified as External Directors.
- Audit Committee: Four directors serving as Audit and Supervisory Committee members were re-elected, three of whom are External Directors.
- Rejected Proposal: A shareholder proposal (Fifth Proposal) to elect one additional director to the Audit and Supervisory Committee was rejected.
Investor Verification Checklist
- Verify the exact dividend payment date and eligibility criteria in the enclosed "Receipt of Year-end Dividends."
- Review the full Consolidated Financial Statements for the 143rd fiscal year (April 1, 2019 – March 31, 2020) to obtain detailed revenue and profit figures not included in this summary.
- Confirm the specific allocation of the 1,100 million JPY director bonus among the three eligible directors.
- Check the official Japanese version of the filing for any discrepancies, as the English translation is for convenience only.